格列齐特 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "格列齐特" in Chinese language version.

refsWebsite

Global rank Chinese rank

15doi.org

2^nd place

23^rd place

14nih.gov

4^th place

5^th place

11web.archive.org

1^st place

3drugs.com

399^th place

208^th place

3medicines.org.uk

3,823^rd place

3,456^th place

3semanticscholar.org

11^th place

332^nd place

2archive.org

6^th place

4^th place

2handle.net

102^nd place

492^nd place

1tga.gov.au

3,984^th place

1,603^rd place

1canada.ca

1,712^th place

3,316^th place

1books.google.com

3^rd place

8^th place

1chemicalbook.com

low place

1,387^th place

1diabetes.ca

low place

1ajkd.org

low place

1wolterskluwer.com

low place

1sciencedirect.com

149^th place

292^nd place

ajkd.org

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update National Kidney Foundation 60 (5): 850–886. November 2012 [2025-02-04]. doi:10.1053/j.ajkd.2012.07.005.

archive.org

British National Formulary : BNF 69 69. British Medical Association. 2015: 474. ISBN 9780857111562.
Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clinical Pharmacology and Therapeutics. October 2003, 74 (4): 334–340. PMID 14534520. S2CID 21519151. doi:10.1016/S0009-9236(03)00221-2 .

books.google.com

Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 449. ISBN 9783527607495. （原始内容存档于2016-12-27）（英语）.

canada.ca

Product monograph brand safety updates. Health Canada. 2016-07-07 [2024-04-03]. （原始内容存档于2024-03-29）.

chemicalbook.com

格列齐特的药理作用. ChemicalBook. 2021-10-11 [2025-02-04]. 参数|title=值左起第1位存在零宽空格 (帮助)

diabetes.ca

guidelines.diabetes.ca

My Site - Special Article: Remission of Type 2 Diabetes. guidelines.diabetes.ca. [2023-06-01]. （原始内容存档于2023-06-02）.

doi.org

Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680.
Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update National Kidney Foundation 60 (5): 850–886. November 2012 [2025-02-04]. doi:10.1053/j.ajkd.2012.07.005.
Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation. August 2004, 34 (8): 535–542. PMID 15305887. S2CID 13636359. doi:10.1111/j.1365-2362.2004.01381.x. hdl:1874/10657 .
Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clinical Pharmacology and Therapeutics. October 2003, 74 (4): 334–340. PMID 14534520. S2CID 21519151. doi:10.1016/S0009-9236(03)00221-2 .
Mégarbane B, Chevillard L, Khoudour N, Declèves X. Gliclazide disposition in overdose - a case report with pharmacokinetic modeling. Clinical Toxicology. April 2022, 60 (4): 541–542. PMID 34698608. S2CID 239887850. doi:10.1080/15563650.2021.1993245.
Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, Ashcroft FM. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. August 2001, 44 (8): 1019–1025. PMID 11484080. doi:10.1007/s001250100595 .
Urbanova J, Andel M, Potockova J, Klima J, Macek J, Ptacek P, et al. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. Current Pharmaceutical Design. 2015, 21 (39): 5736–5748. PMID 26446475. doi:10.2174/1381612821666151008124036.
Ballagi-Pordány G, Köszeghy A, Koltai MZ, Aranyi Z, Pogátsa G. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. January 1990, 8 (2): 109–114. PMID 2106423. doi:10.1016/0168-8227(90)90020-T.
Shimoyama T, Yamaguchi S, Takahashi K, Katsuta H, Ito E, Seki H, et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. June 2006, 55 (6): 722–730. PMID 16713429. doi:10.1016/j.metabol.2006.01.019.
Wang, Shin-Wei; Chang, Shih-Yu. Measurement and modeling of solubility of gliclazide (hypoglycemic drug) and captopril (antihypertension drug) in supercritical carbon dioxide. The Journal of Supercritical Fluids. August 2021, 174 [2025-02-04]. doi:10.1016/j.supflu.2021.105244.
Rieutord A, Stupans I, Shenfield GM, Gross AS. Gliclazide hydroxylation by rat liver microsomes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. December 1995, 25 (12): 1345–1354. PMID 8719909. doi:10.3109/00498259509061922.
Elliot DJ, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. British Journal of Clinical Pharmacology. October 2007, 64 (4): 450–457. PMC 2048545 . PMID 17517049. doi:10.1111/j.1365-2125.2007.02943.x.
Zhang Y, Si D, Chen X, Lin N, Guo Y, Zhou H, Zhong D. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. British Journal of Clinical Pharmacology. July 2007, 64 (1): 67–74. PMC 2000619 . PMID 17298483. doi:10.1111/j.1365-2125.2007.02846.x.
Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology. April 2008, 153 (7): 1579–1586. PMC 2437900 . PMID 18204476. doi:10.1038/sj.bjp.0707685.

drugs.com

Gliclazide - Drugs.com. www.drugs.com. [2016-12-27]. （原始内容存档于2016-12-27）.
Gliclazide Advanced Patient Information - Drugs.com. www.drugs.com. [2016-12-27]. （原始内容存档于2016-12-27）.
GLICLAZIDE 60 MG MR TABLETS DRUG LEAFLET. Drugs.com. [2020-03-23]. （原始内容存档于2019-04-21）（英语）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation. August 2004, 34 (8): 535–542. PMID 15305887. S2CID 13636359. doi:10.1111/j.1365-2362.2004.01381.x. hdl:1874/10657 .

medicines.org.uk

Gliclazide Accord-UK 30mg Prolonged-release Tablets - Summary of Product Characteristics (SmPC). (emc). 2021-02-12 [30 December 2021]. （原始内容存档于2022-09-22）.
Diamicron 30 mg MR Tablets - Summary of Product Characteristics (SmPC). (emc). 2020-05-11 [29 December 2021]. （原始内容存档于2023-12-23）.
Dacadis MR 30mg Modified Release Tablets - Summary of Product Characteristics (SmPC). (emc). 2020-07-15 [2021-12-29]. （原始内容存档于2023-11-08）.

nih.gov

ncbi.nlm.nih.gov

Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680.
Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.
Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation. August 2004, 34 (8): 535–542. PMID 15305887. S2CID 13636359. doi:10.1111/j.1365-2362.2004.01381.x. hdl:1874/10657 .
Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clinical Pharmacology and Therapeutics. October 2003, 74 (4): 334–340. PMID 14534520. S2CID 21519151. doi:10.1016/S0009-9236(03)00221-2 .
Mégarbane B, Chevillard L, Khoudour N, Declèves X. Gliclazide disposition in overdose - a case report with pharmacokinetic modeling. Clinical Toxicology. April 2022, 60 (4): 541–542. PMID 34698608. S2CID 239887850. doi:10.1080/15563650.2021.1993245.
Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, Ashcroft FM. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. August 2001, 44 (8): 1019–1025. PMID 11484080. doi:10.1007/s001250100595 .
Urbanova J, Andel M, Potockova J, Klima J, Macek J, Ptacek P, et al. Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. Current Pharmaceutical Design. 2015, 21 (39): 5736–5748. PMID 26446475. doi:10.2174/1381612821666151008124036.
Ballagi-Pordány G, Köszeghy A, Koltai MZ, Aranyi Z, Pogátsa G. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. January 1990, 8 (2): 109–114. PMID 2106423. doi:10.1016/0168-8227(90)90020-T.
Shimoyama T, Yamaguchi S, Takahashi K, Katsuta H, Ito E, Seki H, et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. June 2006, 55 (6): 722–730. PMID 16713429. doi:10.1016/j.metabol.2006.01.019.
Rieutord A, Stupans I, Shenfield GM, Gross AS. Gliclazide hydroxylation by rat liver microsomes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. December 1995, 25 (12): 1345–1354. PMID 8719909. doi:10.3109/00498259509061922.
Elliot DJ, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. British Journal of Clinical Pharmacology. October 2007, 64 (4): 450–457. PMC 2048545 . PMID 17517049. doi:10.1111/j.1365-2125.2007.02943.x.
Zhang Y, Si D, Chen X, Lin N, Guo Y, Zhou H, Zhong D. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. British Journal of Clinical Pharmacology. July 2007, 64 (1): 67–74. PMC 2000619 . PMID 17298483. doi:10.1111/j.1365-2125.2007.02846.x.
Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology. April 2008, 153 (7): 1579–1586. PMC 2437900 . PMID 18204476. doi:10.1038/sj.bjp.0707685.

pmc.ncbi.nlm.nih.gov

Azimova, Komola; San Juan, Zinnia. Cardiovascular Safety Profile of Currently Available Diabetic Drugs. The Ochsner Journal. 2014 Winter, 14 (4): 616–632 [2025-02-04]. The second-generation sulfonylureas, glimepiride, glyburide (available as glibenclamide outside the United States), glipizide, and gliclazide (not available in the United States), have a lower affinity for CV tissue and may have fewer unfavorable effects, although not all data have been consistent. 请检查|date=中的日期值 (帮助)

sciencedirect.com

Wang, Shin-Wei; Chang, Shih-Yu. Measurement and modeling of solubility of gliclazide (hypoglycemic drug) and captopril (antihypertension drug) in supercritical carbon dioxide. The Journal of Supercritical Fluids. August 2021, 174 [2025-02-04]. doi:10.1016/j.supflu.2021.105244.

semanticscholar.org

api.semanticscholar.org

Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation. August 2004, 34 (8): 535–542. PMID 15305887. S2CID 13636359. doi:10.1111/j.1365-2362.2004.01381.x. hdl:1874/10657 .
Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clinical Pharmacology and Therapeutics. October 2003, 74 (4): 334–340. PMID 14534520. S2CID 21519151. doi:10.1016/S0009-9236(03)00221-2 .
Mégarbane B, Chevillard L, Khoudour N, Declèves X. Gliclazide disposition in overdose - a case report with pharmacokinetic modeling. Clinical Toxicology. April 2022, 60 (4): 541–542. PMID 34698608. S2CID 239887850. doi:10.1080/15563650.2021.1993245.

tga.gov.au

Gliclazide GH MR, Gliclazide LAPL MR, Gliclazide Lupin MR (Lupin Australia Pty Limited). Therapeutic Goods Administration (TGA). 5 December 2022 [2023-04-07]. （原始内容存档于2023-03-18）.

web.archive.org

Gliclazide - Drugs.com. www.drugs.com. [2016-12-27]. （原始内容存档于2016-12-27）.
Gliclazide GH MR, Gliclazide LAPL MR, Gliclazide Lupin MR (Lupin Australia Pty Limited). Therapeutic Goods Administration (TGA). 5 December 2022 [2023-04-07]. （原始内容存档于2023-03-18）.
Product monograph brand safety updates. Health Canada. 2016-07-07 [2024-04-03]. （原始内容存档于2024-03-29）.
Gliclazide Accord-UK 30mg Prolonged-release Tablets - Summary of Product Characteristics (SmPC). (emc). 2021-02-12 [30 December 2021]. （原始内容存档于2022-09-22）.
Diamicron 30 mg MR Tablets - Summary of Product Characteristics (SmPC). (emc). 2020-05-11 [29 December 2021]. （原始内容存档于2023-12-23）.
Dacadis MR 30mg Modified Release Tablets - Summary of Product Characteristics (SmPC). (emc). 2020-07-15 [2021-12-29]. （原始内容存档于2023-11-08）.
Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 449. ISBN 9783527607495. （原始内容存档于2016-12-27）（英语）.
Gliclazide Advanced Patient Information - Drugs.com. www.drugs.com. [2016-12-27]. （原始内容存档于2016-12-27）.
My Site - Special Article: Remission of Type 2 Diabetes. guidelines.diabetes.ca. [2023-06-01]. （原始内容存档于2023-06-02）.
GLICLAZIDE 60 MG MR TABLETS DRUG LEAFLET. Drugs.com. [2020-03-23]. （原始内容存档于2019-04-21）（英语）.
Gliclazide. Lexicomp. Wolters Kluwer N.V. [2023-06-01]. （原始内容存档于2023-06-02）.

wolterskluwer.com

Gliclazide. Lexicomp. Wolters Kluwer N.V. [2023-06-01]. （原始内容存档于2023-06-02）.